Harrow (HROW) vs Latigo Biotherapeutics (LTGO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Harrow is the larger company by market cap ($1.10 billion vs $1.06 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HROW | LTGO |
|---|---|---|
| Share price | $29.36 | $16.00 |
| Market cap | $1.10B | $1.06B |
| 1-day change | -3.80% | +8.18% |
| YTD return | -40.08% | — |
| 1-year return | -27.63% | — |
| 5-year return | +196.87% | — |
| Forward P/E | 10.59 | — |
| EPS (TTM) | $-0.99 | $-2.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $54.85 | $25.93 |
| 52-week low | $27.00 | $14.60 |
| Distance from 52-week high | -46.47% | -38.30% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +121.39% | +226.56% |
| Average volume | 555.55K | 391.26K |
| Shares outstanding | 37.49M | 66.30M |
| Employees | 373 | 66 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Harrow
HROW stock →Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 373 employees
About Latigo Biotherapeutics
LTGO stock →Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction.
Health Care · Biotechnology: Pharmaceutical Preparations · 66 employees
HROW vs LTGO FAQ
Which is bigger, Harrow or Latigo Biotherapeutics?
Harrow (HROW) is larger, with a market capitalization of $1.10B compared with $1.06B for Latigo Biotherapeutics (LTGO).
Are Harrow and Latigo Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.